Taiwan's Adimmune To Submit New H1N1 Vaccine Bid To Government
This article was originally published in PharmAsia News
Executive SummaryThe biopharmaceutical outfit Adimmune says it expects to become the only supplier of an A/H1N1 vaccine in Taiwan despite a law that requires at least three companies bid for government orders. Adimmune submitted a bid to supply 5 million doses of an H1N1 vaccine to the Department of Health, but the tender failed because only Adimmune submitted a bid. The department said it would open a second tender this week, but would not require a minimum number of bidders or a preset price range, in line with an interpretation of the Government Procurement Act. An Adimmune spokesman said the firm would submit a new tender. (Click here for more
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.